% | $
Quotes you view appear here for quick access.

Alimera Sciences, Inc. (ALIM) Message Board

mickmack50 73 posts  |  Last Activity: Jun 25, 2015 10:00 PM Member since: Dec 2, 2010
  • mickmack50 mickmack50 May 20, 2015 9:00 PM Flag

    To me, you're worth. I just won't write the check.

  • Reply to

    Market Not Excited

    by godwintom May 20, 2015 4:04 PM
    mickmack50 mickmack50 May 20, 2015 8:56 PM Flag

    Tom, We've been waiting for these catalysts for a long time haven't we. At the same time, it's not that holders of pSivida stock are selling. I think they're hoping and waiting for the very things we are. Even short attacks are few these days. It seems someone is there to buy the dips. At the same time, there are sellers of the 10 cent pop. So, what's my point......Any of the positives you mentioned could happen tomorrow. The market seems content with keeping pSivida right where it is. No one's getting excited about moving in or moving out. I do like the fact that there are now big global's looking at Durasert and Tethadur. So, there are a few companies more familiar with what pSivida is doing than the market is. Typical. I guess that what risk is all about. Thanks for checking in.

  • mickmack50 mickmack50 May 20, 2015 11:00 AM Flag

    It's a data issue. Let's face it the data will either drive the SP up or down. The last bit of dat is a great example.
    Latanoprost has better efficacy, just all by itself. I'm not short, but it makes a lot more sense at this point. The company at this point is way over valued. All you're doing is spending money.

  • Reply to

    Wet AMD

    by mdhe51 May 20, 2015 9:48 AM
    mickmack50 mickmack50 May 20, 2015 10:15 AM Flag

    md, You begin to wonder, it may not be the drug so much as it is a sustained release method. Ashton keeps talking about drugs that may work in a sustained release platform (re-purposed drugs). I'd say pSivida goes after wet now. Obviously, a drugs efficacy is a factor, but the overall efficacy of the drug may be big time enhanced with micro gram exposure on a daily basis, and over the years. I've watched LPTN for years. Sad their drug candidates aren't working as hoped.

  • Reply to

    Medidur Interim Data

    by mickmack50 May 19, 2015 9:16 AM
    mickmack50 mickmack50 May 19, 2015 11:44 AM Flag

    JD, I guess we've both pondered these very points regarding big pharma interest. Perhaps sbwill's point is well taken. If there is limited analyst coverage on a company like pSivida, then until there is, there may be no particular hurry for any of the bigs to jump in. But, let's get back to your revenue points and pSivida. Medidur data will rock. I think they hit it out of the park with efficacy and safety data. Assuming so, and jumping to approval of the NDA in 17' what sort of market share could pSivida expect out of the 175K/annual posterior Uveitis patients? Lets' just say 15% for a round number (though I think much more) . Just 15% market share of this patient pool at 8K/dose is $210Million. This does not include Iluvien profit split which could be at least half of that. So, though it's a piece down the road, the market potential of just Medidur and Iluvien could be 8-10 bucks a share or more. This does not include other partnerships or collaborations related to further Durasert platform licenses going forward. Let's not even bring up Tethadur.
    So, you're right, where is big pharma? Well, you and I both know, they're engaged already. Let's just look at Pfizer, they just recently filed a form 13D.....peculiar perhaps, as the last 10Q of pSivida addresses potential deviations from their stated agreement with PFE. It sounds to me like they're working as close together as ever. Go read the PFE form 13D and pSivida's last 10Q, maybe something is up. Either way, it's going to be exciting to see how it plays out. Forget the current SP, that could change dramatically overnight. Big Pharma does the math better than any of us.

  • mickmack50 by mickmack50 May 19, 2015 9:16 AM Flag

    We have a ways to go. But the Durasert license to ALIM did not include posterior Uveitis. There is a reason for that. pSivida has a pretty good grasp on this indication. After all, Retisert had dealt with the condition well, but it had a fairly serious side effect with elevated IOP. Now, Medidur for the same indication has solved some of those IOP issues. Today's interim data reflects that. Just a 10% market share of the posterior Uveitis market would be very large indeed. Remember, it's not only the FA drug here, it's the platform that delivers tiny micro grams on a daily basis to the site. So, expanding this to dry's as much the delivery vehicle of Durasert that gives greater efficacy to a potential myriad of drugs, with daily micro gram delivery over years. Off patent, repurposed drugs used more effectively for various eye indications, all based on better delivery over time. What a concept.

  • Just to show what a epic narcissistic sociopath this guy is.....In his own words....

    antisense_science •

    I have enough shares to be in the top 4 major investors of the Co. So Sum The Forces Up. You probably bought a few thousand shares in the 50c -$1 and think you know it all. And no, I don't think it is about me, it is about the shareholders of this Co and how their money is utilized or wasted and the power of the CEO's office is abusing the cash in hand. There is absolutely no justification of giving these guys any stock based comp. because they tend to hold nothing. They are as bad as Lynn Parshall of Isis Pharma from the days back when she was CFO. If the CFO keeps selling everything she gets, what confidence does she show in the Co? Same questions is valid to these insiders who automatically keep selling everything. Stock based Comp. is not meant for the insiders to get paid bonuses regardless of how the Co. performs, it is not like they are taking $1 salary until they can show growth in this Co. Even Steve Jobs was an #$%$ who stole from Apple by backdating his stock options.
    CEOs have no conscience they think it is Con Science. Cheerleader investors like you is the reason they get away with the loot. Go give them a P-S-D-V-I-S-A-S-H-T-O-N..... Less

    Now, I wonder if he's filing with the SEC, knowing that he's got such a large position. Just to refresh everyone's memory.
    Here are the top shareholders as of 3/31/15
    Allan Gray (formerly Orbis) 2,320,455
    North Run Capital 2,144,086
    Vanguard 707,346
    Paul Ashton 440,741
    Morgan Stanley 323,788
    Perceptive Advisors 315,000
    Bridgeway Capital Management 201,900

    Remember, he's only here to keep us focused on the right and true path......Thanks, Moron.

  • Reply to

    So, Let's Just Look At Who We're Working With....

    by mickmack50 May 12, 2015 11:05 AM
    mickmack50 mickmack50 May 18, 2015 9:24 PM Flag

    Ex, I'd hold for any one of potential catalysts going forward. Since your basis is good, I'd just hold until something really good happens. At some point we've got to be acquired. Does this mean this year or next? Not sure. But with a little more sauce in the pot it could start to boil. It's all up to you bud. I'm just holding for Tethadur clarity and license deals ultimately. But even with clarity I'm a holder until we get snapped up by one of the bigs. Is it a certainty? No it's not. Still, we're way undervalued. GL.

  • mickmack50 mickmack50 May 18, 2015 9:11 PM Flag

    Oh yeah, I'm just so sure. Top 4 of the major shareholders huh? What a *&^%$ dooshbagger. Everything after that is just more*&^%$

  • Reply to

    EBIO for Dry eye....

    by terry290737 May 18, 2015 7:53 AM
    mickmack50 mickmack50 May 18, 2015 1:06 PM Flag

    Terry, I was looking into this company not long ago. Forgot they had this PIII trial with upcoming data due. Another overpriced clinical stage bio takes a hit. There seems to be a pattern and it's not a good one of late. Then there is pSivida, unknown, unloved and undervalued at four bucks.

  • mickmack50 mickmack50 May 16, 2015 8:13 PM Flag

    Kool, Thanks, this guy wants it yesterday and thinks it's all about him.......and his hundred shares.

  • mickmack50 mickmack50 May 15, 2015 9:45 AM Flag

    I bet you're popular during the holidays. People must be stacking up just to
    hang with you.

  • mickmack50 mickmack50 May 14, 2015 9:31 PM Flag

    JD, I think as it relates to the progress of the big pharma and the evaluation in ophthalmology, they are dictating the release of news. As pSivida is talking about and stating so in their 10K and Q's, we're on the right track. Time will take it's course and data will be data. As Ashton said, "Tethadur continues to show enormous promise". I'm going to take his word for that. By the way, this isn't price in either, like at all. If it's good, it will be very good indeed.

  • mickmack50 mickmack50 May 14, 2015 5:22 PM Flag

    I am still a believer in the fundamentals of the company. Iluvien , in and of itself, will more than pave the way to profitability for the company. No future is priced in at these levels. This being said, your four years was torture, we were all here together for it. No data coming as stated by management regarding Tethadur continues to be frustrating, the Iluvien saga was torture. Thanks for your thoughts and input. I will however hold for more clarity on Tethadur. If pSivida can deliver them in a consistent way, which is what I believe they're working on, then this is a Billion dollar company. It is my belief that Paul Ashton does in fact know exactly what he's doing here. Medidur data will rock, I guarantee it; granted it's a wait. I do however thank you for your thoughts. I wish you well in your other investing ventures.

  • Reply to

    Ashton's chops

    by tblew May 11, 2015 12:25 PM
    mickmack50 mickmack50 May 13, 2015 5:53 PM Flag

    TBLOW. Ashton brought with him the technology to make Iluvien, a three year release of micro grams that defines the therapeutic affect No one else has done it since. Are you and Nonsense in bed together in your mothers basement? Ashton's still working on Tethadur with the likes of Roche or Regeneron. Please, give it a rest, cut your losses and get fricken' gone from this MB with your whining sentiment. Biatching is all you bring to us. That's it...#$%$, #$%$.....What a fricken doosh.

  • Reply to

    So, Let's Just Look At Who We're Working With....

    by mickmack50 May 12, 2015 11:05 AM
    mickmack50 mickmack50 May 12, 2015 1:40 PM Flag

    David, It's the smallest of companies with the brightest of future and potential. The fact that pharma is jumping on Durasert, pSivida's cornerstone platform for small molecules that can deliver drugs over
    3 years.....who would be interested in that? I think they start stacking up like cord wood. Thanks for your input here.

  • Pfizer, Roche or Regeneron, and a newbie Big Pharma, who wants to get into Ophthalmology?
    I say this is why Paul Ashton is quiet. He can't blow the horn until he gets the OK from any one
    of the Bigs. I say we're in great company and our valuation is 120Million.....I mean c'mon. Iluvien
    is going to easily generate revenues to cover that in just a few years.

  • Reply to

    Iluvien coverage on Fox news

    by ruraddy May 11, 2015 11:08 AM
    mickmack50 mickmack50 May 12, 2015 10:14 AM Flag

    Yep, great piece. It's about people not going blind. This is just the tip of the iceberg.

  • "These" evaluation agreements, mean more than one. By a "global pharmaceutical company" means deep pockets and "funded" means revenue. C'mon guys, this is how the industry works. Until pSivida has a bit more than proof of concept, it's slow and steady. I hope it's for "DRY EYE". Ashton spoke very confidently on his last couple calls regarding the pre-clinical work looking very promising. "Dry" is a much bigger market than "Wet", like 5 times, and we see what Eylea has done for REGN in just the Wet indication. I believe this gets the ball rolling for pSivida and with Durasert approved by the FDA, with a long, steady sustained release of micrograms of therapeutics, over years. This is why the platform is so valuable. Drugs right where it's needed , slowly over years. Back of the eye diseases are tough and this is how it's dealt with. I'm still way in.

  • mickmack50 mickmack50 May 12, 2015 9:21 AM Flag

    Terry. These are still ongoing. With one being either Roche or Regeneron, why on earth do we rush it? If we need to work some bugs out.........these are many BILLIONS OF DOLLARS worth of drugs. Isn't Ashton allowed to get it right here?

4.63+0.04(+0.87%)Jul 6 4:00 PMEDT